Phenethylisothiocyanate Potentiates Platinum Therapy by Reversing Cisplatin Resistance in Cervical Cancer

Elizabeth Mahapatra; Debomita Sengupta; Ravindra Kumar; Budheswar Dehury; Salini Das; Madhumita Roy; Sutapa Mukherjee

doi:10.3389/fphar.2022.803114

Phenethylisothiocyanate Potentiates Platinum Therapy by Reversing Cisplatin Resistance in Cervical Cancer

Front Pharmacol. 2022 Apr 25:13:803114. doi: 10.3389/fphar.2022.803114. eCollection 2022.

Authors

Elizabeth Mahapatra¹, Debomita Sengupta¹, Ravindra Kumar², Budheswar Dehury³, Salini Das¹, Madhumita Roy¹, Sutapa Mukherjee¹

Affiliations

¹ Department of Environmental Carcinogenesis and Toxicology, Chittaranjan National Cancer Institute, Kolkata, India.
² School of Biotechnology, National Institute of Technology Calicut, Kozhikode, India.
³ ICMR-Regional Medical Research Centre, Chandrasekharpur, Bhubaneswar, India.

Abstract

Acquired cisplatin resistance in cervical cancer therapy is principally caused by reduction in intracellular drug accumulation, which is exerted by hyperactivation of the oncogenic PI3K/Akt signaling axis and overexpression of cisplatin-exporter MRP2 along with prosurvival effectors NF-κB and IAPs in cervical cancer cells. These activated prosurvival signaling cascades drive drug efflux and evasion of apoptosis for rendering drug-resistant phenotypes. Our study challenges the PI3K/Akt axis in a cisplatin-resistant cervical cancer scenario with phenethylisothiocyanate (PEITC) for chemosensitization of SiHa^R, a cisplatin-resistant sub-line of SiHa and 3-methylcholanthrene-induced cervical cancer mice models. SiHa^R exhibited higher MRP2, p-Akt^Thr308, NF-κB, XIAP, and survivin expressions which cumulatively compromised cisplatin retention capacity and accumulated PEITC better than SiHa. SiHa^R appeared to favor PEITC uptake as its accumulation rates were found to be positively correlated with MRP2 expressions. PEITC treatment in SiHa^R for 3 h prior to cisplatin exposure revived intracellular platinum levels, reduced free GSH levels, generated greater ROS, and altered mitochondrial membrane potential compared to SiHa. Western blot and immunofluorescence results indicated that PEITC successfully downregulated MRP2 in addition to suppressing p-Akt^Thr308, XIAP, survivin, and NF-κB expressions. In mice models, administration of 5 mg/kg body-weight PEITC priming dosage prior to treatment with 3 mg/kg body-weight of cisplatin remediated cervical histology and induced tumor regression in contrast to the group receiving the same dosage of cisplatin only. This suggested PEITC as a potential chemosensitizing agent in light of acquired cisplatin resistance in cervical cancer and established its candidature for Phase I clinical trial.

Keywords: MRP2; PEITC; PI3K/AKT; chemosensitization; cisplatin resistance.